Sarepta Therapeutics, Inc. (SRPT)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Douglas S. Ingram Esq. | President, CEO & Director | 1.66M | -- | 1963 |
| Mr. Ian Michael Estepan | Executive VP & CFO | 1.01M | -- | 1976 |
| Mr. Bilal Arif | Executive VP & Chief Technical Operations Officer | 829.72k | -- | 1972 |
| Dr. Louise R. Rodino-Klapac Ph.D. | Executive VP, Chief Scientific Officer and Head of Research & Development | 1.03M | -- | 1978 |
| Mr. Ryan E. Brown J.D. | Executive VP, Chief General Counsel & Corporate Secretary | 887.47k | -- | 1978 |
| Ms. Francesca T. Nolan | Executive Director of Investor Relations and Corporate Communications | -- | -- | -- |
| Ms. Alison Nasisi | Executive VP & Chief People Officer | -- | -- | -- |
| Dr. Diane L. Berry Ph.D. | Executive VP and Chief of Global Policy & Advocacy Officer | -- | -- | -- |
| Mr. Dallan Murray | Executive VP & Chief Customer Officer | -- | -- | -- |
| Mr. Will Tilton | Senior VP, Head of Strategy & Chief of Staff | -- | -- | -- |
Sarepta Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 1,314
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
July 31, 2024 at 10:59 AM UTC - August 5, 2024 at 12:00 PM UTC
Sarepta Therapeutics, Inc. Earnings Date